Comparable Efficacy of Once-Daily Versus On-Demand Vardenafil in Men with Mild-to-Moderate Erectile Dysfunction: Findings of the RESTORE Study

European Urology

Volumn 54, Issue 1, 2008, Pages 204-212

  Zumbé, Jurgen ^a   Porst, Hartmut ^b   Sommer, Frank ^c   Grohmann, Walter ^d   Beneke, Manfred ^e   Ulbrich, Ernst ^e  

^a KLINIKUM LEVERKUSEN   (Germany)

^b Private Practice   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d Private Practice   (Germany)

^e BAYER AG   (Germany)

Author keywords

Erectile dysfunction; Impotence; Phosphodiesterase type 5 inhibitors; Vardenafil

Indexed keywords

PLACEBO; VARDENAFIL;

ADULT; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DYSPEPSIA; ERECTILE DYSFUNCTION; FLUSHING; FOLLOW UP; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEXUAL SATISFACTION; SIDE EFFECT;

DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ERECTILE DYSFUNCTION; GERMANY; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; SULFONES; TREATMENT OUTCOME; TRIAZINES;

EID: 44149125039     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.03.056     Document Type: Article

References (22)

1. Schwarz E.R., Kapur V., Rodriguez J., Rastogi S., and Rosanio S. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res 19 (2007) 139-148
2. Ziegler D., Merfort F., van Ahlen H., Yassin A., Reblin T., and Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 3 (2006) 883-891
3. Rubio-Aurioles E., Porst H., Eardley I., and Goldstein I. Comparing vardenafil and sildenafil in the treatment of men with erectile dysfunction and risk factors for cardiovascular disease: a randomized, double-blind, pooled crossover study. J Sex Med 3 (2006) 1037-1049
4. Padma-Nathan H. PDE-5 inhibitor therapy for erectile dysfunction secondary to nerve-sparing radical retropubic prostatectomy. Rev Urol 7 suppl 2 (2005) S33-S38
5. Aversa A., Bruzziches R., Pili M., and Spera G. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des 12 (2006) 3467-3484
6. McMahon C.G. Treatment of erectile dysfunction with chronic dosing of tadalafil. Eur Urol 50 (2006) 215-217
7. Reginster J.Y., Rabenda V., and Neuprez A. Adherence, patient preference and dosing frequency: understanding the relationship. Bone 38 (2006) S2-S6
8. World Health Organization. Adherence to long-term therapies: evidence for action. Vol 2006. Basel: World Health Organization; 2003.
9. McMahon C. Comparison of efficacy, safety, and tolerability of on-demand tadalafil and daily dosed tadalafil for the treatment of erectile dysfunction. J Sex Med 2 (2005) 415-425 discussion 425-7
10. Wharton J., Strange J.W., Moller G.M., et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 172 (2005) 105-113
11. Proietti M., Aversa A., Letizia C., et al. Erectile dysfunction in systemic sclerosis: effects of longterm inhibition of phosphodiesterase type-5 on erectile function and plasma endothelin-1 levels. J Rheumatol 34 (2007) 1712-1717
12. Osinski M.T., Rauch B.H., and Schror K. Antimitogenic actions of organic nitrates are potentiated by sildenafil and mediated via activation of protein kinase A. Mol Pharmacol 59 (2001) 1044-1050
13. Ferrini M.G., Kovanecz I., Nolazco G., Rajfer J., and Gonzalez-Cadavid N.F. Effects of long-term vardenafil treatment on the development of fibrotic plaques in a rat model of Peyronie's disease. BJU Int 97 (2006) 625-633
14. Sommer F., and Schulze W. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors. World J Urol 23 (2005) 385-392
15. Rosano G.M.C., Aversa A., Vitale C., Fabbri A., Fini M., and Spera G. Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 47 (2005) 214-222 (discussion 220-2)
16. Porst H., Giuliano F., Glina S., et al. Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol 50 (2006) 351-359
17. Aliaev Iu G., Vinarov A.Z., and Akhvlediani N.D. Therapeutic efficacy of a course administration of vardenafil-inhibitor of phosphodiesterase-5-in erectile dysfunction. Urologiia 1 (2007) 45-46
18. Rosen R.C., Riley A., Wagner G., Osterloh I.H., Kirkpatrick J., and Mishra A. The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 49 (1997) 822-830
19. DiBenedetti D.B., Gondek K., Sagnier P.-P., et al. The treatment satisfaction scale: a multidimensional instrument for the assessment of treatment satisfaction for erectile dysfunction patients and their partners. Eur Urol 48 (2005) 503-511
20. Porst H., Rajfer J., Casabe A., et al. Long term safety and efficacy of 5 mg tadalafil dosed once daily in men with erectile dysfunction. J Sex Med 5 (2008) 62
21. Sáenz de Tejada I. Vardenafil duration of action. Eur Urol 50 (2006) 901-902
22. Porst H., Sharlip I.D., Hatzichristou D., et al. Extended duration of efficacy of vardenafil when taken 8 hours before intercourse: a randomized, double-blind, placebo-controlled study. Eur Urol 50 (2006) 1086-1095 (discussion 1094-5)